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Abstract 
Aims: 1) Identify the presence and characterize the plasmatic isoforms of Receptor 
Type Protein Tyrosine Phosphatase Gamma (PTPRG) 2) Characterization of new 
monoclonal antibodies specific for the extracellular domain of the protein. 
Background: PTPRG is a broadly expressed enzyme mainly expressed in lung, 
stomach, esophagus, colon, liver, spleen and kidney. PTPRG maps to chr 3p14.2/21 and 
has been implicated as a candidate tumor suppressor gene. Loss of eterozigosity, gene 
deletion, point mutation and promoter hypermethylation has been reported. The 
majority of the receptor PTP share similar intracellular domains while the extracellular 
portion exhibits broad structural variation. Rat brain has been reported to express 
various PTPRG isoforms, including the isolated extracellular region 1. Previous work 
from our group suggested the production on an extracellular soluble form of PTPRG in 
thyroid 2 . 
Methods: immunoprecipitation, western blotting, flow cytometry.  
Results: We have identified, in human and murine plasma, new PTPRG isoforms, one 
of which  previously characterized by cDNA cloning only in rat 1. The polypeptides 
identified have an apparent  MW of about 120 kDa (major band) and 90 kDa (minor 
band) respectively. Surprisingly, also the full length protein, that include a 
transmembrane region, was identified in the serum and was present in the fraction 
precipitating at 100000 ×g, suggesting the presence of an exosome-associated form. The 
major band (120 kDa) was also identified in mouse liver (isolated after saline perfusion 
in order to remove plasma) and in serum-free conditioned medium derived from 
HepG2, an hepatocellular carcinoma cell line commonly used for the study of the 
regulation of hepatic protein synthesis. The 120 kDa isoform was up-regulated by 
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treatment with ethanol and potassium dichromate, two compounds known to be 
cytotoxic for liver 3-5. With the future goal to set up an ELISA-based assay for the rapid 
screening of soluble PTPRG expression in various physiopathological conditions, we 
have developed and characterized two new monoclonal antibodies raised against the 
extracellular domain of PTPRG expressed in eukariotic cells (HEK 293F). 
Conclusion: We have described for the first time in human and mouse the presence of 
soluble, plasmatic forms of PTPRG that appear to be released primarily by liver. The 
major 120 kDa band appear to be glycosylated and its expression is modulated by 
stimuli known to produce liver injury. 
The production and initial characterization of new monoclonal antibodies capable to 
specifically recognize this protein here described will permit the set up of new 
immunoassays and will pave the way to a better characterization of this proteins and its 
role in health and disease.  
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Introduction 
Kinase/Phosphatase in cell signaling 
The importance of phosphorylation and the regulatory role of protein kinases is 
established. However, it has become apparent that protein phosphatases can no longer 
be viewed as passive housekeeping enzymes in these processes. Instead, the kinases and 
phosphatases are partners, and their activities are coordinated in the regulation of 
signalling responses. The distinct but complementary function of these enzymes is 
emphasized by recent studies in which the kinases have been implicated in controlling 
the amplitude of a signalling response, whereas phosphatases are thought to have an 
important role in controlling the rate and duration of the response 6. If overexpression of 
tyrosine kinases or mutations that would render them constitutively active would bring 
about oncogenicity then, necessarily, overexpression of tyrosine phosphatases would 
block or reverse transformation, even if the accumulation of experimental evidence have 
rendered the picture much more complex 7. 
 
Protein Tyrosine Phosphatases 
Following the discovery and the purification of the first PTP (PTP1B) in 1988 from 
human placenta 8 and the identification of the first transmembrane PTP (CD45) 9, many 
other PTPs have been cloned on the basis of sequence homology in the catalytic 
domain. 
The human genome contains 107 PTPs, with the class I cysteine-based PTPs 
constituting the largest group. This group can be further subdivided into 61 dual-
specificity phosphatases and 38 tyrosine-specific PTP genes, the “classical PTPome”.  
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Classical PTPs have been further subdivided into receptor (R1–R8) and 
nontransmembrane (NT1–NT9) subgroups 10, 11. Twelve receptor PTPs have two 
catalytic domains (tandem domains), while the remaining PTPs all have a single 
catalytic phosphatase domain. In tandem-domain receptor protein tyrosine phosphatases 
(RPTPs), it is the PTP (D1) domain adjacent to the plasma membrane that displays 
catalytic activity while the PTP (D2) domain is either inactive or has negligible catalytic 
activity11. The functional role of the D2 domain has not yet been defined although 
possible roles in regulating RPTP stability, specificity, and dimerization have been 
suggested. Furthermore, all RPTPs, with the exception of PTPRA and PTPRE contain 
large and diverse extracellular regions that regulate cell contacts and adhesion 12. 
 
 
Figure 1: Schematic representation of Cys-based PTPs and their substrate specificity, 
(part of 10). 
 
Protein Tyrosine Phosphatase gamma (PTPRG) 
PTPRG was originally cloned from human brain stem and placental cDNA libraries 
using probes derived from the intracellular domain of CD45. PTPRG is a gene mapped 
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in chromosome 3p14-p21 : 61,547,243-62,283,288 in the forward strand. The gene have 
11 spliced variants and 6 of this are known to harbor protein coding sequence 
(http://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000144724).  
 
 
Figure 2: Schematic representation of PTPRG gene. Transcripts that are protein coding, from 
Ensembl database: http://www.ensembl.org/Homo_sapiens/Gene/Summary?g= 
ENSG00000144724. 
 
The full length PTPRG is composed of a 30 exons and produce a 1445 amminoacid- 
length protein. The gene have a 5’UTR region inside the first exon that include the 
consensus sequence for sp1 factor (-410/-405 bp), a CCAAT BOX (-228/-224 bp) and a  
TATA BOX (-30/-25 bp) upstream the starting codon and have a 3’UTR region at the 
end of the exon 30.  
This PTP belong to a subtype V of the receptor tyrosine phosphatase and  possesses an 
extracellular region, a single transmembrane region and two tandem intracytoplasmic 
catalytic domains. The extracellular region of this PTP contains a carbonic anhydrase-
like (CAH) domain and a fibronectin type three domain which is also found in the 
extracellular region of PTPRZ. 
 
Expression of the PTPRG protein in cells and normal and neoplastic tissues 
Membranous and⁄or cytoplasmic PTPRG expression was detected in leukocytes, 
including hemopoietic precursors, the vast majority of epithelial cell types and 
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endocrine cells of various organs 13 14 15. In summary, in humans PTPRG was described 
as a marker for CD34+ cells, monocytes, dendritic cells and specialized macrophages. It 
is also expressed in all the epithelia of the gastrointestinal tract (including stomach, 
small and large bowel mucosa and appendix) and most cells of the genitourinary system 
(proximal and distal tubules of the kidney, endometrium, fallopian tubes, prostate 
glands). PTPRG expression was also found in breast and ducts of parotid and sweat 
glands. In the liver, hepatocytes were strongly immunopositive, whereas bile ductules 
were faintly stained. Squamous epithelia, including epidermis, oral cavity, oesophagus 
and uterine cervix, strongly expressed PTPRG. Epithelial cells showing inconsistent and 
rather faint immunoreactivity included urothelium, bronchial mucosa, gallbladder and 
large bile ducts. In the lung, the epithelia of bronchioli, pneumocytes and macrophages 
were all immunoreactive. Neither T- or B-lymphoid cells appear to express PTPRG as 
assessed by immunohistochemistry of thymus and lymph nodes, while a strong signal 
was associated with sinus macrophages. Remarkably high expression of PTPRG was 
found in endocrine cells of the gastrointestinal tract, pancreatic islet of Langerhans, 
adrenal medulla and thyroid. Interestingly, thyroid follicular cells were stained with 
both intracellular and extracellular antibodies, while the colloid was strongly positive 
only using the extracellular one. Among non-epithelial cells, PTPRG was expressed by 
endothelia of various organs, including spleen sinusoids and high endothelial venules in 
lymph nodes. Immunoreactivity was also intense in the smooth muscle layer of the wall 
of larger vessels. Variable staining was detected in fibroblasts of connective tissue. 
Striated and smooth muscle cells were strongly immunopositive for PTPRG, while fat 
cells were immunopositive, but inconsistently so. In the peripheral nervous system, 
PTPRG was regularly expressed by ganglion cells within the myenteric plexus. In the 
central nervous system, positivity was detected in some scattered cells with elongated 
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nuclei and a few dendritic cell processes that probably represent elements of the 
microglia. Purkinje cells of the cerebellum and some neuronal elements were also 
positive. 
 
PTPRG in neoplasia 
PTPRG is a candidate tumor suppressor gene and mutations, deletion or loss of 
eterozigosity are associated with different type of tumor. 
In lung carcinoma (LC) tumor samples PTPRG expression was down-regulated in 
tumor cells only, but still expressed in the normal, interstitial cells. The PTPRG 
suppression in 50% of the human lung adenocarcinomas confirms and extends on the 
protein level the suggestion of LaForgia et al 16 that reported PTPRG gene deletion in 
two out of five human lung adenocarcinoma cell lines. Such non-sporadic deletions of 
PTPRG are thought to signify the presence of a gene(s) whose functional inactivation is 
involved in the malignant process. 
In ovarian cancer the expression of PTPRG was reduced in both the tumor cells and 
the normal interstitial cells 2, 15. 
The translocation t(3;8) of the familiar renal cell carcinoma (RCC) occurs inside the 
5’ end of PTPRG gene but the 6-Kbp coding sequence was not disrupted by the 
translocation. Since tumor suppressor genes involved in specific type of familial cancer 
are often involved in development of sporadic tumors of the same type, it seemed likely 
that if the 3p14 locus encompassing the translocation breakpoint harbors a suppressor 
gene, this region would also be involved in allele loss in sporadic RCCs. 89% of RCCs 
exhibit a common region allele loss17. 
Weak PTPRG expression in breast cancer compared to normal tissue correlated with a 
higher estrogen receptor status ERα and a lower ERβ expression. Inhibition of PTPRG 
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RNA expression by estradiol in primary-cultured normal breast cells and in breast 
cancer cell lines suggesting that PTPRG may be a potential estrogen-regulated tumor 
suppressor gene in human breast cancer, which might thus play an important role in 
mammary epithelium neoplastic transformation 18. In keeping with this finding, over-
expressing PTPRG can antagonize the estrogenic effects of 17β-estradiol on cell 
proliferation which indicates its anti-estrogenic effects on human breast cancer19.  
Mutational analysis of the tyrosine phosphatome in colorectal cancer display 83 
somatic mutation in six PTPs including PTPRG where 8 point mutation (7 missense and 
1 LOH) were detected 20. 
Malignant T cells of patients with CTCL display widespread promoter 
hypermethylation associated with inactivation of several tumor suppressor genes 
involved in DNA repair, cell cycle and apoptosis signaling pathways including 
PTPRG21. 
The PTP expression profile obtained in gastric cancer sample revealed a strong 
representation of a few PTPs such as PTPRG, PTPRA and PTPRC, which occupied 
more than 70% of the clones that were analyzed. PTPRG expression level was high in 
normal human gastric tissue while is reduced in cancer22. Difference exists in DNA 
methylation between primary tumor and metastatic lymph nodes of gastric cancer, 
where the gene seems to be more methylated in the metastasis than in the primary tumor 
that suppress the expression of the gene23. 
PTPRG was identified as a candidate tumor suppressor gene in nasopharyngeal 
carcinoma (NPC) by differential gene profiling of tumorigenic and nontumorigenic 
NPC. Down-regulation of this gene was found in NPC cell lines and tumor biopsies. 
Promoter hypermethylation and loss of heterozygosity were found to be important 
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mechanisms contributing to PTPRG silencing. PTPRG overexpression in NPC cell lines 
induces growth suppression and reduced anchorage-independent growth in vitro 24. 
 
Type of tumor Type of mutation 
Familial renal cell carcinoma (RCC) t(3;8) Translocation, LOH 
Lung Cancer Down regulation by gene deletion, LOH 
or protein down modulation 
Breast cancer Down regulation 
Colorectal Cancer Point mutations  
CTCL (cutaneous T-cell lymphoma) Promoter hypermethylation 
Gastric cancer Down expression of the protein 
Nasopharyngeal carcinoma Promoter hypermethylation, LOH 
 
Table 1: Summary table of the mutations reported for each type of tumor. 
 
Regulation of extracellular domain of Receptor Type PTP (PTPR) 
The ectodomains  of some PTPRs are cleaved off by specific protease and remain bound 
extracellularly to the citoplasmic region of these PTPs 25. In addition, these ectodomains 
may be shed, and thus may have a function by themselves, acting as ligands, 
independently of the catalytic activity of the enzyme. The most appealing function of 
the ectodomains that may bind ligands that somehow induce an alteration of the 
intracellular PTP activity.  
PTPRF (LAR) is a 1881 amminoacid protein with a MW of about 200 kDa that is 
cleaved intracellularly into two subunits: P-subunit with a intracellular portion, 
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transmembrane peptide and a short segment of the extracellular region that are then 
non-covalently associated to the E-subunit (consisting of the extracellular domain of the 
protein). The extracellular portion can be released from the cell surface 25. 
PTPRA and PTPRE are two other PTPs subjected to proteolytic cleavage. The cleavage 
is calpain-mediated and produce, from the larger PTPRA and PTPRE proteins, a 
processed form of about 66kD and 65kDa, respectively. The cleavage occurs in close 
proximity to the wedge domain, a region that participates in significant intermolecular 
interactions in the course of phosphatase dimerization. Proteolytic cleavage and 
subcellular re-distribution of these protein can affect the physiological function with a 
gain or loss of function. The truncated form of PTPRA is less able to dephosphorylate a 
substrate than the full length PTPRA, but the translocation of the truncated protein can 
access to potentially new substrate in the cytosol26. 
PTPRU is a phosphatase that undergoes posttraslational cleavage into two non-
covalently associated subunits 27. The concentration of the full length  protein is up 
regulated in cell density-dependent inhibition of growth  and the increase of the 
expression is associated with an increase in its proteolytic cleavage. This processing of 
PTPRU may have an important role in contact inhibition of cell 28. 
After the cloning of PTPRK, a tyrosine phosphatase of about 210 kDa, in 1993, the 
generation of a product of an unexpected smaller size was observed. PTPRK protein 
consists of two subunits that are noncovalently attached to each other: the 
transmembrane P subunit (100 kDa) that harbors two PTP domains and the extracellular 
E subunit (120 kDa) that covers most of the extracellular sequence. Both subunits are 
generated from one precursor protein by proteolytic processing at the dibasic cleavage 
site (RTKR) located within the membrane proximal fibronectin type III domain. 
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The two cleavage products remain associated after cleavage and may be considered 
subunits of a single complex; this association is not mediated by a disulfide linkage 29. 
The processing of the protein is accomplished by sequential proteolytic processing by 
three proteases at three sites. While the first cleavage by furin participates in RPTP 
maturation in the secretory pathway, cleavage at the second site by ADAM 10 (nearest 
to the transmembrane  in the extracellular domain) results in the shedding of the 
phosphatase extracellular fragment. Finally, intramembrane proteolysis at third site by 
γ-secretase releases the intracellular domain of the protein to the cytoplasm. In this 
proteolytic pathway, processing by ADAMs may play a major regulatory role 30. 
It is known that three isoforms of Ptprz are generated by alternative splicing from a 
single Ptprz gene in rat: two transmembrane isoforms, Ptprz-A (full length isoform) and 
Ptprz-B (a deletion variant missing an 860 amino acid in the extracellular domain 
juxtamembrane), and a secretory isoform named Ptprz-S31. 
Ptprz-A and Ptprz-B can undergo further processing by metalloproteinase-mediated 
ectodomain shedding, which releases the extracellular fragment ZA/B-ECF(extracellular 
fragment), from the cell surface and produces the membrane-tethered counterpart Z∆E. 
Z∆E is digested by PS/γ-secretase, and the cytoplasmic fragment Z-ICF (intracellular 
fragment) is released from the plasma membrane and is detected not only in the 
cytoplasm but also in the nucleus, suggesting a novel signaling pathway driven by Ptprz 
32
. 
Finally four different isoforms of Ptprg have been identified in rodents of which one is 
represented by a soluble form. 
Ptprg isoforms are derived from alternative splicing, and are designated as ptprg-A (full 
length isoform), ptprg-B (lacking the intracellular juxtamembrane 29 amino acid) 33, 
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ptprg-C that have only one phosphatase domain and ptpr-S an extracellular variant of 
the protein that is secreted into culture medium when expressed in COS7 cells 1. 
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Aims of the study 
In order to better study the role of plasmatic PTPRG isoforms we needed to determine 
the type of protein present, its origin and to develop suitable tools for its identification 
and measure, ideally suited for high-throughput assays. To this end  we also needed to 
generate new monoclonal antibodies. In this thesis I will go through a series of data that 
will try to answer to these critical issues.  
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Material and methods 
 
Patient samples: 
Preparation of plasma and serum 
Plasma was obtained from healthy blood donors from buffy coats or from whole 
peripheral blood. Peripheral blood was drawn from normal healthy donors into EDTA 
tube and spun down at first at 335 ×g for 15 minutes and then the supernatant at 3000 x 
g for 15 min in a Heraeus Megafuge 1.0R. Plasma was drawn off and used immediately 
or frozen at 80 °C until use.  
The serum was processed as the plasma sample after coagulation of blood sample in 
EDTA free tube. 
All the samples derived from the transfusion blood bank of the University and Hospital 
Concern of Verona (Italy). 
 
Antibodies 
The antibodies used were:  
1) anti-PTPRG rabbit polyclonal antibody P4 (Rb anti-P4) obtained against 
immunity of rabbit with a synthetic peptide 
(CGSDPKRPEMPSKKPMSRGDRFSED amino acids 687-710 named P4) 
coupled, through an NH2-terminal cysteine, to KLH (Sigma Chemical Co., St. 
Louis, MO). 33.  
2) anti-PTPRG chicken polyclonal antibody (Ch-PTPRG) obtained against the 
synthetic peptide (CZ NED EKE KTF TKD SDK DLK (amino acids 390-407 ) 
and produced by Aves Labs (Tigard, OR, USA) 34. 
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3) anti-human/mouse/rat PTPR gamma monoclonal antibody, MAB4608 (R&D 
Systems, Minneapolis, USA).  
4) polyclonal anti-PTP gamma rabbit antibody (ab37525) a KLH-conjugated 
synthetic peptide (10-30 amino acids in length) in the region of 791-807 of 
Human PTP gamma (Abcam Inc., Cambridge, USA). 
5) two monoclonal antibodies anti PTPRG extracellular domain developed in our 
laboratory (described in following paragraph). 
6) rabbit isotype control IgG: Chrompure Rabbit IgG, whole molecule (011-000-
003 Jackson Immuno Reserch laboratories, inc., Baltimore Pike , USA). 
7) chicken isotype control (IgY, chicken IgG) from pre-immunized chicken from 
Aves Labs (Tigard, OR, USA).  
8) mouse IgG (015-000-003 Jackson Immuno Reserch laboratories, inc., Baltimore 
Pike , USA) and mouse IgM isotype control (Sigma St. Louis, MO, USA). 
All the antibodies were used according to the manufacturer’s instructions.  
 
 
Table 2: Schematic representation of antibody against PTPRG utilized in this study. 
Epitope: aminoacid number of epitope, based on ENST00000474889 protein sequence. Tested 
application: IP= immuno-precipitation, WB= western blot, IHC= immunohistochemistry, Flow= 
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flow cytometry. The PTPRG schematic image (right) display where the epitopes of the antibody 
are localized within the predicted protein sequence The colored arrows localize the epitopes 
relative to the antibodies shown in the table with the corresponding colors *33, ** 34. 
 
Recombinant Protein and monoclonal antibodies 
The extracellular domain of PTPRG linked to mouse Fc (PTPRG-ECD-Fc), fusion 
protein between PTPRG extracellular domain (amino acid 1-736) and mouse-Fc IgG3 
(aminoacid 1-237) used as protein tag, and the control protein Fc, were produced in our 
laboratory in HEK 293F cell line and affinity purified following standardized protocols. 
The recombinant protein PTPRG-ECD-Fc was used as epitope for the immunization, as 
immunogen for the ELISA screening and as standard for the glycosylation experiments. 
The mouse hybridoma cell lines were produced by ARETA International srl (Gerenzano 
VA, Italy) from BALB-C mouse that has been challenged with PTPRG-ECD-Fc. The 
screening of the different clone and subcone produced by ARETA were first evaluated 
by direct ELISA using the purified protein as antigen and the control protein Fc in order 
to remove all the clone reacting against the tag.
 
Subclones were screened on the basis of 
capability to recognize the native antigen by flow cytometry. Two clones: Mab 6E2-B6 
(IgG) and Mab 12G5-B10 (IgM) were chosen for further analysis. 
 
Cell culture 
HepG2 cell (human, Caucasian, liver, carcinoma, hepatocellular, ATCC HB 8065) were 
cultured in EMEM containing 2mM glutamine, 1mM Na pyruvate and 10% heat-
inactivated Fetal Calf Serum (FCS) or cultured in serum free medium. HepG2 cell were 
cultured in SF medium with 25, 6.25 µM of potassium dichromate (Sigma-Aldrich, 
Milan, Italy) and 400, 200, 100 mM ethanol (VWR, Milan, Italy). 
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Transfected HEK 293F cells were cultured in RPMI 1640 containing 10% heat-
inactivated Fetal Calf Serum (FCS), 4mM glutamine, and 0,5 mg/ml of hygromycin 
(Invitrogen Milan, Italy) as selective agent or cultured in serum free medium CD293® 
(Gibco, Milan, Italy) with 50 µM di β-mercaptoethanol and 0,5 mg/ml of hygromycin 
(Invitrogen, Milan, Italy). All the cultured cells were grown at 37°C, in 5% CO2. 
 
Cells and tissue lysate  
20x106 cells/1 ml were solubilized in lysis buffer (LB) containing 50 mM Tris (pH 7.4), 
1% Triton X-100, 150 mM NaCl, 200 µM NaVO4, 1 mM EDTA, 1 mM DTT, 1 mM 
NaF, Complete EDTA-free Protease Inhibitor Cocktail Tablets (Roche) incubated for 20 
min. in a rotating wheel at 4°C and centrifuged for 30 min at 4 °C at 13000 ×g in a 
Biofuge Pico, (DJB Labcare Ltd. UK). Normal tissues isolated from PBS-perfused mice 
were frozen in liquid nitrogen vapors and stored at –80°C. A series of 20 µm cryostat 
coronal sections were lysed in cold LB and processed as previously described. All the 
procedures were carried out at 4°C. 
 
Ultracentrifugation and supernatant precipitation  
Serum free conditional medium (SFCM) and plasma were ultra-centrifuged at 100000 
×g for 2 h at 4°C in analytical ultracentrifuge Beckman Optima XL-A (Beckman 
counter Inc., Brea, CA, USA). The supernatant was transferred in a fresh tube while the 
pellet was resuspended in SDS-PAGE sample buffer (SB). Proteins were precipitated 
from the SFCM by addition of trichloroacetic acid (TCA) to a final concentration of 
10% under continous stirring at 4°C overnight. Following centrifugation at 3000 ×g for 
30 minutes at 4° C, the pellet was washed twice with a mixture of cold acetone / 
methanol 8:1 and pelleted at 13000 ×g for 15 minutes at 4°C. The pellet was dried in a 
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speed-vac (Savant SVC 100H Speed Vac Concentrator, Phoenix Equipment Inc. AZ, 
USA) for 30 minutes. The dried pellet was the resuspended in 20 µl of SB. Plasma 
samples was ultra-centrifuged as SFCM and treated as indicated. 
 
Flow cytometry 
Cells (monocyte and Hep G2) were washed twice with PBS buffer, blocked with 1 µg 
of Human IgG (Sigma St. Louis, MO, USA) for 15 minutes at RT and then incubated 
with Ch-PTPRG, Rb anti-P4 antibody (2 µg/106 cells) or mouse IgG 6E2-B6 / IgM 
12G5-B10 (1 µg/106 cells) and with suitable isotype control for 1 hour on ice. After one 
wash with PBS buffer cells were stained with goat anti-chicken Alexa488, goat anti-
rabbit Alexa488 or goat anti-mouse Alexa488 IgG/IgM (Invitrogen, Milan, Italy) for 30 
min at RT. Flow cytometry was performed on a Becton Dickinson FACScan®. Analysis 
of data was performed with FCS Express V3 software (De Novo Software).  
Purified cells (monocyte) were purified by Percoll (Pharmacia Uppsala, Sweden) 
gradient centrifugation from leukocyte rich buffy coats obtained from human blood of 
healthy donors, as described elsewhere 35.  
 
Immunoprecipitation with Cyanogen-bromide activated Sepharose 4B 
4 mg antibody /0,286 g gel and the same quantity for an isotype control was coupled to 
Cyanogen-bromide activated Sepharose 4B (Sigma, Missuri, USA) according to the 
manufacturer’s protocol. 
Plasma samples from blood donors and patients were diluted 1:5, 1:10, 1:20, 1:40 in 
PBS/TX100 1% to a final volume of 500 µl and added with 5 µl of Cyanogen-bromide 
activated Shepharose 4B with Rb anti-P4 and its control (RbIgG isotype). After three 
hour in a rotating wheel, beads were washed three time with PBS and the pellet were 
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mixed with SB (to a final concentration of 40 mM Tris-HCl pH 6.8, 183 mM β-
mercaptoethanol, 1% SDS, 5% glycerol) and denatured at 95°C for 10 minutes.  
 
Immunoprecipitation with Protein G Sepharose 4 Fast Flow  
Total protein content was assessed using Bradford assay 36 (Sigma, Missuri, USA). 
Serum-free conditioned medium (SFCM) or cell lysate (250 µg of total protein for each 
sample) were incubated with 3 µg of specific antibodies for 3h at 4°C. Beads (cat n:17-
0618-01 GE Helthcare, Little Chalfont, UK) were centrifuged and washed one time in 
Tris-buffered saline (TBS) and three times in LB or serum free medium before the 
immunoprecipitation. 20 µl of protein G-Sepharose (Sigma St. Louis, MO, USA) for 
each sample was added and left for 1 h at 4°C with gentle rocking. Following three 
washes in TBS buffer the pellet was resuspended in SB and incubated at 95°C for 10 
minutes and subjected to SDS-PAGE. 
 
Deglycosylation 
Deglycosylation of purified recombinant extracellular domain of PTPRG linked to Fc 
(ECD-PTPRG-Fc) and the immunoprecipitated plasmatic PTPRG was carried out with 
the use of PNGase F (Boehringer, Mannheim, Germany) according to the 
manufacturer’s protocol.  
 
Western blot 
Cell lysate, serum free supernatant of cells (HEK 293F transfected with a PTPRG-ECD- 
Fc and Fc carrying vectors) and tissues lysate were resolved on 10% SDS-PAGE and 
electroblotted onto polyvinylidene difluoride membrane (Millipore Corp., Bedford, 
MA). The membrane were blocked with 3% BSA for polyclonal antibody and 5% BSA 
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for the monoclonal, in TBS, 0.05 % Tween-20 (TBST) and probed with suitable 
antibodies at 1 µg/ml in 1% BSA TBST buffer o.n. After washes in TBST, the 
membrane was then incubated with the following secondary antibody: 1) donkey anti-
rabbit IgG-HRP (GE Helthcare, Little Chalfont, UK), 2) goat anti-mouse-HRP 
conjugated (GE Helthcare, Little Chalfont, UK) or 3) with anti mouse Fc-HRP 
conjugated (NOVUS biological, Littleton, CO, USA) for 1 h. After washing with TBST, 
the signal was detected with the enhanced chemiluminescence kit (Millipore Corp., 
Bedford, MA). 
 
Mice perfusion and tissue collection.  
Male C57BL/6J wild-type mice, 5–8 weeks of age, were purchased from The Jackson 
Laboratory (Bar Harbor, ME, USA). The mice were maintained under specific 
pathogen-free conditions. All experiments were performed in accordance with the 
Animal Care and Use Committee guidelines. 
The mice were anesthetized with an i.p. injection of Ketamine/Xilazina (80-100mg/kg 
Ketamina and 10mg/kg Xilazina in PBS). Following abdominal incisions, the heart of 
the mice were perfused with Phosphate Buffer Saline (PBS), 22 mM glucose, 1 mM 
CaCl2 and 1 mM MgCl2 through the left ventricle of the heart using Masterflex Pump 
Controller (Cole Parmer Instrument Co., Chicago, IL, USA) at a flow rate of 4 ml per 
minute. This flow rate approximates the murine physiological blood pressure. When all 
the blood was replaced with the saline solution organs (brain, thymus, heart, lung, 
kidney, spleen, liver and pancreas) were removed, snap-frozen with dry ice, and stored 
at -80°C. A series of 20 µm cryostat coronal sections were lysed in LB. Quality of the 
tissue was checked with Hematoxyilin-Eosine staining. Equal protein amounts were 
mixed with SB, subjected to SDS-PAGE and electroblotted on nitrocellulose 
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membrane. Immunoblotting was done with two polyclonal antibodies (Rb anti-P4 and 
Ch-PTPRG). 
 
MTT assay 
Yellow MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
tetrazole) (Sigma, Missuri, USA)  is reduced to purple formazan in the mitochondria of 
living cells. The absorbance of this colored solution can be quantified by measuring at 
570 nm by a spectrophotometer. This reduction takes place only when mitochondrial 
reductase enzymes are active, and therefore conversion can be directly related to the 
number of viable (living) cells. When the amount of purple formazan produced by cells 
treated with an agent is compared with the amount of formazan produced by untreated 
control cells, the effectiveness of the agent in causing death of cells can be deduced, 
through the production of a dose-response curve. Mitochondrial dehydrogenases of 
viable cells cleave the tetrazolium ring, yielding purple MTT formazan crystals which 
have been dissolved in DMSO and the absorbance read at 570 nm.  
HepG2 cells were seeded at 10.000 cell/well in 96-well flat bottom culture plates and 
incubated overnight, the day after were exposed to different concentration of potassium 
dichromate and ethanol diluted in complete medium and serum free medium and 
incubated for 24 h. The SFCM were collected and processed . About 10 µl of MTT (5 
mg/ml) was added to each well and incubated for 3 h. The formazan dye formed was 
extracted with 100 µl of DMSO.  
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Results 
Detection of PTPRG isoform in plasma/serum 
We performed immunoprecipitation (IP) of six different mouse serum and a lot of 
human plasma samples (fig 3 B display one representative sample) with polyclonal anti-
PTPRG-RbgG P4 linked to Cyanogen-bromide activated Sepharose 4B and subsequent 
detection by Immunoblotting with the same antibody that readily displayed the full 
length protein,  a specific band about 120 kDa and a band of 90 kDa (Fig 3).  
 
Figure 3: Plasmatic isoforms. A: Immunoblotting with Rb anti-P4 of immunoprecipitated 
serum samples diluted 1:20 in PBS/Tx100 1%. lane 1-5 ,7: IP with Rb anti-P4. lane 6: RbIgG 
isotype control. B: Immunoblotting with Rb anti-P4 of immunoprecipitated human serum 
diluted 1:20 in PBS/Tx100 1%. Lane 1 IP with isotype control lane, 2: Rb anti-P4. Green arrow: 
full lenght protein, yellow arrow: 120 kDa isoform, blu arrow: 90 kDa isoform.  
 
For a better understanding of PTPRG processing we first evaluated if the full length of 
the protein found in plasma was linked to the plasma membrane in the form of small 
particles released by the cells and known as exosomes.  
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To this purpose we have analyzed plasma samples  before and after ultra-centrifugation 
at 100000 ×g, a speed that is known to preciptate these nanoparticles known to be 
present in plasma (fig 4). As we could detect the FL protein in the pelleted fraction, we 
can conclude that the FL protein is likely associated to plasma-membrane particles 
defined as “ectosome” or “exosome” 37. Both 120 kDa and 90 kDa isoforms are  present 
in plasma after ultra-centrifugation, and therefore represent soluble plasmatic isoforms. 
                       
 
Figure 4: Identification of a plasmatic PTPRG isoform. Immunoblotting with Rb anti-P4 
antibody of immunoprecipitated serum samples (serum sample 1: lane 1,3,5; serum sample 2: 
2,4,6) diluted 1:10 in PBS/Tx100 1% with the same antibody. Lane 1,2: serum sample before 
100000 ×g ultracentrifugation. Lane 3,4: same plasma sample after ultracentrifugation. Lane 
5,6: pellet derived from the ultracentrifugation.  
 
PTPRG glycosylation 
Based on sequence analysis we predicted an extracellular domain form of 81 kDa while 
the protein we detected has an apparent MW of about 120 kDa. This discrepancy could 
be explained by the occurrence of glycosylation, a typical feature in extracellular 
domains of many receptor-like polypeptides. Indeed the treatment with Glycopeptidase 
F (PNGase F), a deglycosilant enzyme, determined a reduction of MW from 120 to 
about 100 kDa. PGNaseF cleaves asparagines linked high mannose as well as hybrid 
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and complex oligosaccharides from glycoproteins. It deaminates the asparagine to 
aspartic acid, but leaves the oligosaccharide intact. The same shift in MW was observed 
using the PTPRG-ECD-Fc (Fig 5). The slightly higher molecular weight of the 
recombinant protein  is due to the presence of a fusion cDNA with a murine Fc tag.  
                                 
 
Figure 5: Extracellular PTPRG is present as a glycoprotein in human plasma. 
Immunoblotting with Rb anti-P4 of purified recombinant PTPRG-ECD-Fc lanes 1,2 and 
immunoprecipitated plasma samples (lane 3-6) and. Lane 1-4: IP Rb anti- P4, lane 5-6: IP 
RbIgG isotype controls. Lanes 2, 4, 6: same samples of lanes 1, 3 and 5 treated with the 
deglycosilating enzyme PNGase F.  
 
PTPRG isoforms 
For a better characterization of the soluble isoforms of PTPRG we performed 
immunoprecipitation of plasma followed by immunoblotting using four different 
antibodies (whose features are described in Tab 2). Figure 6A summarizes the results: 
all the antibodies recognize the full length protein (green arrow), the 120 kDa protein is 
recognized by all the antibodies raised against the extracellular domain (lane 1,2 A and 
B). The 90 kDa isoform (light blue arrow) is detected with all the antibody recognizing  
PTPRG including the intracellular epitope, suggesting the conservation of the 
transmembrane domain in this isoform (lane 3). The Abcam antibody (the more N-
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terminal antibody) recognize also a band around 80 kDa that need to be better 
characterized. In fig 6B a IP from plasma followed by a imunoblotting with the same 
antibody (Ch-PTPRG) is shown. This experiment permit to recognize a doublet around 
120 kDa probably due at different state of glycosylation of the ECD, known to be 
highly glycosylated. One of these bands is apparently not recognized by the anti-P4 
antibody.  
 
 
Figure 6: Characterization of plasmatic PTPRG isoform. A:Immunoblotting with: Rb anti-
P4 (lane 1), mouse monoclonal R&D (lane 2), rabbit polyclonal Abcam (lane 3) of 
immunoprecipitated human plasma samples. Lanes 1-3: IP with Rb anti-P4 anti PTPRG. B: 
Immunoblotting with chicken polyclonal anti PTPRG of the plasma sample immunoprecipitate 
with the same antibody. Green arrow: full lenght PTPRG, yellow arrow: PTPRG 120 kDa 
isoform, light blue arrow: 90 kDa isoform.  
 
Expression in murine tissues 
The second aim of this study was the identification of the tissue/s that produce the 120 
kDa isoform. As a plasmatic form of the protein has been detected, we needed to 
remove any trace of plasma from tissues before performing the analysis. This was 
accomplished by perfusion of all the organs with saline as described in material and 
methods section. The full length protein is detectable in almost all the tissues examined. 
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A fainter band was detected in pancreas while no protein was detected in kidney. A 120 
kDa protein was readily detectable only in liver (fig 7). 
 
                       
Figure 7 PTPRG expression in mouse tissues. Immunoblotting with Rb anti-P4 antibody. 
20µg of lysate from perfused tissues were loaded on 10% SDS-PAGE.  
 
In order to better characterize the antigen, immunoprecipitation followed by western 
blotting was also performed on the same samples (fig 8).  
 
Figure 8: Characterization of PTPRG isoforms in mouse serum and selected organs. 
Immunoblotting from IP mice serum and mice tissue lysate (250 ug each for the tissues). Lane 
1,2 :mice serum 1:IP CN-Br RbIgG isotype , 2: IP CN-Br Rb anti-P4. Lanes 3, 5, 7, 9, 11, 13, 
15: IP Protein G Sepharose  Rabbit IgG Isotype control. Lane 4, 6, 8, 10, 12, 14, 16: IP Protein 
G Sepharose Rb anti-P4. Western blotting was reacted with Rb anti-P4 antibody. 
 
None of the tissues investigated express detectable levels of the 120 kDa isoform. In all 
the tissue examined a single band corresponding to the full-length membrane form of 
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PTPRG was detected. Moreover, immunoblot assay highlight a band of approximately 
70 kDa in all the tissues investigated (with the exception of kidney) that need to be 
better characterized.  
A more detailed analysis of liver samples highlight the presence of two specific bands 
of approximately 120 and 90 kDa that are also detected in plasma/serum (Fig 9A). The 
90 kDa band react with and antibody raised agains a juxtamembrane intracellular 
domain, thus indicating that this isoform retains epitopes located on both sides of the 
transmembrane region (fig 9B).  
 
 
 
Figure 9. PTPRG isoforms present in liver. Panels A and B : Immunoprecipitation from 
mouse serum (lane 1,2) and liver lysates (3-6) IP with Rb anti-P4 (lane 2, 4-6) or with RbIgG 
isotype (lane 1,3). Lane 1,2 :IP CN-Br , 3-6 :IP Protein G Sepharose.  
Panel A: WB with Rb anti-P4 reacting against an epitope located in the extracellualr domain. 
Panel B: WB with polyclonal anti PTPRG (791-807 R&D ) reacting against an epitope located 
in the intracellular domain of PTPRG. Yellow arrow :120 kDa and light blu arrow: 90 kDa 
isoform. 
 
Hep G2 cell model 
Searching for experimental models capable to overcome the typical limitations of 
primary tissues we have chosen the HepG2, a cell line derived from an hepatocellular 
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carcinoma. HepG2 cells are used routinely for a variety of biochemical and cell 
biological assays addressing hepatocyte functions. These cells secrete a variety of major 
plasma proteins; e.g., albumin, transferrin and the acute phase proteins fibrinogen, alpha 
2-macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen and represent the 
most commonly used cell line for examining the regulation of hepatic protein synthesis. 
We have first evaluated the protein expression by flow cytometry (fig. 10).  
 
Figure 10: PTPRG expression in Hep G2. Flow cytometric analysis of Hep G2 cell line. 
Staining with A: Rb anti-P4 B: Ch-PTPRG (blue lines). Isotype control staining is shown in red.  
 
Subsequently cell lysate and conditioned medium (protein precipitation from serum free 
(SF) medium of HepG2) were analyzed. The result confirmed the presence of 120 and 
90 kDa found in plasma and liver tissue samples with the excepition of the full length 
protein in SFCM (fig. 11).  
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Cytotoxic compounds increase PTPRG release in Hep G2 cells.  
Potassium dichromate is a widespread industrial waste while ethanol abuse represent a 
common cause of liver injury. HepG2 cells were treated in vitro with different doses of 
these compounds in order to evaluate whether they can modulate the release of the 120 
kDa PTPRG isoform. MTT assay indicate a stronger cytotoxic effect of potassium 
dichromate when compared with ethanol. We measured the number of cells as 
calculated from the relationship among cell number/ OD (optical density at 570 nm) in 
MTT assay (Fig. 12) for correlate the OD with the cells number. 
                     
Figure 12: MTT assay. Correlation between the Optical density (OD) at 570 nm and cells 
number.  
 
Figure 11: Expression of PTPRG isoforms in 
Hep G2 cells. Lane 1: 10 µg of Hep G2 cell line 
total cell lysate. Lane 2: serum free supernatant 
of  HepG2 after 100000 ×g ultra-centrifugation 
and TCA precipitation. WB with Rb anti-P4. 
Green arrow: FL protein, yellow arrow : 120 kDa 
isoform light blue arrow: 90 kDa isoform. 
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We have then quantified the amount of the 120 kDa isoform present in the conditioned 
medium from the same pooled wells, after 24 hours of incubation. The value was 
expressed as density (pixel intensity in a 256 grayscale/mm2). Finally we correlated 
these values as a ratio among density of PTPRG isoform/number of live cells present in 
the well at the end of the experiment. Both stimuli induce the release of higher amounts 
of the 120 kDa isoform (2 to 7 fold) in comparison with the control (fig 13).  
 
 
Figure 13: Cytotoxicyty induce the release of the extracellular PTPRG isoform in Hep G2 
cells. Immunoblotting with Rb anti-P4 antibody of SFCM derived after 24 hours treatment with 
the indicated drugs. Column 1: number of viable cells /well (+/- standard deviation); in column 
2 the % of cell viability compared to the not treated cells. In column 3 is reported the optical 
density (INT/mm2) of the 120 kDa band in the different SFCM while column 4 indicate the ratio 
between the density and the number of viable cells (ratio among columns 3 and 1). In 
parentheses in column 4 is indicated the fold increase relative to the not treated sample made 
equal to 1.  
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Characterization of mAb against ECD of PTPRG 
The study of a soluble form of PTPRG require the development of suitable 
immunodetection assays. A single monoclonal antibody (mAb) raised against the 
extracellular domain produced in prokaryotes (lacking the post-translational processing 
typical of eukaryotes) have been commercialized only very recently. We have isolated 
two monoclonal antibodies produced  against the fully glycosilated ECD purified from 
eukaryotic cells.  
We selected two mAb for their capability to recognize the purified  PTPRG ECD by 
ELISA and the native antigen expressed by peripheral blood leukocytes34 as detected by 
flow cytometry. In. fig 14 a representative staining of the two mAb in comparison with 
the validated Ch-PTPRG antibody is shown. 
 
Figure 14: Flow cytometry analysis of human purified monocytes. Staining with A: ch-
PTPRG B: 6E2-B6 C: 12G5-B10. Isotype control staining is shown in red. 
 
To better characterize the features of these new antibodies we evaluated their capability 
to recognize the protein by immunoprecipitation and western blot on the recombinant 
extracellular domain. We analyzed the SFCM from HEK 293F cells transfected with 
either a PTPRG ECD cDNA truncated at the level of the putative transmembrane region 
linked to mouse Fc IgG3 or with the control vector expressing only the Fc tag.  
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The 12G5-B10 IgM antibody specifically recognize, by western blotting, the predicted 
120 kDa band in the gel lane loaded with the SFCM containing the recombinant extra 
cellular domain, being the supernatant derived from Fc transfected cells negative. The 
identity of the band was further confirmed by its reactivity with anti mouse Fc antibody 
(fig 15). In the cell lysate only the anti-Fc antibody was able to recognize the immature, 
not glycosylated form of the protein. This antibody does not immunoprecipitate the 
protein (not shown). 
 
Figure 15: Characterization of 12G5-B10 mAb. HEK 293F cells lysate (1,2) and SFCM (3,4). 
Line 1,3 cells transfected with PTPRG-ECD-Fc, line 2,4 cells transfected with Fc control. A: 
WB detection with anti mouse Fc. B: detection with mAb anti PTPRG 12G5-B10. Yellow 
arrow: mature soluble ECD-Fc. Purple arrow: intracellular precursor form.  
 
The 6E2-B6 IgG antibody is able to immunoprecipitate the mature, secreted form in 
SFCM and cell lysates and the immature not glycosilated form present in the cytosol 
(fig 16) 
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Based on these results we conclude that 1) the 12G5-B10 IgM antibody is capable to 
recognize the protein by western blot and 2) 6E2-B6 IgG is capable to 
immunoprecipitate the native protein 3) both the antibodies can recognize the native 
protein by direct ELISA and by flow cytometry. 
 
Figure 16: Characterization of 6E2-B6 IgG 
mAb.  Immunoprecipitation of HEK 293F 
cells SFCM (1,2) and cell lysate (3,4) with 
mAb 6E2-B6 and WB detection with Rb anti-
P4. Lanes 1,3 cells transfected with PTPRG-
ECD-Fc, lanes 2,4 cells transfected with Fc 
control. Yellow arrow: mature soluble ECD-
 36 
 
 
Discussion 
In general terms, soluble and membrane-bound isoforms of the same protein can be 
generated by one of two mechanisms: 1) separate biosynthetic pathways, either by 
alternative pre-mRNA splicing of a common transcript or by transcription of closely 
related but distinct genes; 2) by posttranslational release of the extracellular domain of 
membrane proteins by hydrolytic cleavage of the membrane anchor. The latter appears 
to represent a useful and commonly employed device that allows cells to multiply the 
functional roles of proteins with a minimum investment in energy and structural 
complexity. Membrane proteins are apparently specifically released by proteolysis in a 
directed and sometimes regulated manner to produce active, soluble forms. These 
include proteins that are sufficiently diverse in structure and function to suggest that 
limited proteolysis may constitute a general mechanism in the release of membrane 
proteins to generate soluble isoforms with defined functions 38. 
We have discovered the presence of a soluble PTPRG form in human and mouse 
plasma and serum samples. The identification of a PTPRG soluble form represent a 
novel finding because until now this isoform was detected only in cell culture medium 
of transfected cells or as  mRNAs transcript in the neonatal rat brain 1. Furthermore two 
glycopeptides derived from the ECD of PTPRG protein (amino acid number: 95-115 
and  433-448) were identified in human serum within a large scale glycoproteomic 
analysis 39, thus confirming that a plasmatic form of this PTP is present. 
Except from these data nothing else is present in the current scientific literature. Human 
blood plasma possesses significant potential for disease diagnosis and therapeutic 
monitoring even if it appear to be an extremely complex tissue. Indeed it appear to 
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contain not only “classic” plasma proteins, but also cellular “leakage” proteins that can 
potentially originate from virtually any cell or tissue type in the body. However, thanks 
to its accessibility and to the possibility to detect various kind of molecules associated 
to the cell metabolism, protein abundance changes in plasma may provide direct 
information on physiological and metabolic states of disease and drug response. As a 
result, the discovery of novel candidate protein biomarkers from plasma sample could 
open a new avenue of investigation in this challenging field.  
In this study we have identified different PTPRG soluble isoforms present in human and 
mouse plasma including the full length PTPRG protein. Given its structural features that 
include a transmembrane domain, this form is probably linked to the plasma membrane 
associated to cell-derived exosomes. The detection of a major band of about 120 kDa 
protein detected with all the antibody available for PTPRG extracellular domain 
suggests that this isoform represent the complete ECD described by others 1. An 
additional isoforms we detected include a 90 kDa protein (present in human/mouse 
plasma, murine liver, in the lysate and SFCM of HepG2 cell line), and a 70 kDa protein, 
detected in all the perfused tissues analyzed. 
Taking advantage by the use of a large series of antibodies, most of which developed in 
our laboratory, we can conclude that the 90 kDa protein may be missing a part of the N-
terminal of the ECD and possess a short tail of the intracellular domain, as it reacts with 
an antibody raised against an epitope located in this region. A possibility exists that 120 
kDa protein and the 90 co-immunoprecipitate under the experimental conditions used in 
our assays. This last interpretation is suggested by the observation that the association 
of E and P subunits of PTPRF (LAR), not disulfide bonded, was stable under standard 
cell lysis condition and was sufficiently strong to resist disruption during vigorous 
washing of the immunoprecipitates 25. Also PTPRS was expressed in two subunits that 
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were derived from a precursor protein by proteolytic processing and also in this case E 
and P subunits co-imunoprecipitate 40. The visualization of the 120 and 90 kDa isoforms 
in HepG2 cell line and in liver of perfused mice support the hypothesis that the liver 
produces a soluble form of extracellular domain that is released in plasma of healthy 
donor. The analysis of PTPRG expression in organs highlight the presence of a 70 kDa 
band that might represent an immature deglycosylated form of the soluble protein or a 
fragment of the 120 kDa isoform lacking part of the C-terminal domain of the ECD. 
We now need to correlate ECD relese to a specific function and/or physiophatological 
condition. In order to start to address this issue we first wonder whether cytoxicity could 
alter the release of this protein in the extracellular space. For this purpose we used the 
Hep G2 cell model and observed  that potassium dichromate and ethanol induced an 
increased amount of the released 120 kDa isoform. 
 
The question whether the soluble form of PTPRG could reflect a specific 
physiopathological condition require the study of a large series of clinical information-
rich plasma samples and the development of medium-high throughput screening assays. 
One of the most widely utilized in research and clinical biochemistry, is represented by 
ELISA assays. Unfortunately this assay is not currently available for this protein for the 
absence of suitable antibodies. Given this premise, we decided to develop new reagents 
capable to react against the native form of this PTP in the form of monoclonal 
antibodies.  
The immunization procedure gave rise to several clones, two of which were selected for 
further characterizaton.  6E2-B6 and 12G5-B10 recognize the native protein by ELISA 
and flow cytometry assays. In addition, 6E2-B6 mAb was capable to recognize the 
native, full-length PTPRG protein by immunoprecipitation. The mAb 12G5-B10 
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specifically recognized the eukaryotic recombinant ECD expressed in HEK 293F cells 
by western blotting but  could not detect the unprocessed cytoplasmic form in the same 
cells. This could be related to a lower affinity for this antigen or the different protein 
folding patterns, since immature PTPRG proteins could result in the exposure of unique 
immunogenic epitopes different from those present in the folded proteins. An 
alternative explanation, that we favor as the antibody recognize the fully processed 
protein released in the extracellular space, is that the epitope recognized by this 
antibody is glycosilated. Future experiments will better address this issue. 
In summary, we generated two new mAbs that may provide suitable reagents for further 
investigation of the functional role of PTPRG proteins and open the possibility to 
quantify the native protein in cells and biological fluids derived from patients. This, in 
turn, will provide the necessary informations to unravel the role of sPTPRG in health 
and disease.  
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